12 filings
8-K
SYRE
Spyre Therapeutics Inc.
3 Dec 19
Regulation FD Disclosure
8:00am
8-K
SYRE
Spyre Therapeutics Inc.
6 Nov 19
Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
8:30am
8-K
SYRE
Spyre Therapeutics Inc.
27 Sep 19
Departure of Directors or Certain Officers
7:30am
8-K
SYRE
Spyre Therapeutics Inc.
3 Sep 19
Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium
6:03am
8-K
SYRE
Spyre Therapeutics Inc.
6 Aug 19
Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
8:00am
8-K
amgyn6x10x58rq5f kw
7 Jun 19
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
kjlqz74
7 May 19
Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights
7:45am
8-K
vnjq mpihnewn
3 May 19
Entry into a Material Definitive Agreement
5:05pm
8-K
5x18vbteb944w26
8 Apr 19
Regulation FD Disclosure
6:05am
8-K
68z9twqn
8 Mar 19
Departure of Directors or Certain Officers
4:30pm
8-K
5zxdsqt u4fdjz
7 Mar 19
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
4:05pm
8-K
mbke27mm
6 Feb 19
Entry into a Material Definitive Agreement
9:40pm
- Prev
- 1
- Next